Condition: Tumor Skin · Metastatic Melanoma · Melanoma · Sponsor: Obsidian Therapeutics, Inc.
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
This description comes directly from the study's public registry record.
Obsidian Therapeutics · 781-202-5423 · OBX115-2301TRIAL@OBSIDIANTX.COM
Always discuss trial participation with your own doctor first.
| The Angeles Clinic and Research Institute (Melanoma) | Los Angeles, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center (Melanoma/NSCLC) | Los Angeles, California, United States | Recruiting |
| Stanford Cancer Institute (Melanoma/NSCLC) | Stanford, California, United States | Recruiting |
| Orlando Health Cancer Institute (Melanoma/NSCLC) | Orlando, Florida, United States | Recruiting |
| James Graham Brown Cancer Center (Melanoma/NSCLC) | Louisville, Kentucky, United States | Recruiting |
| Memorial Sloan Kettering (Melanoma/NSCLC) | New York, New York, United States | Recruiting |
| The Ohio State University | Columbus, Ohio, United States | Active Not Recruiting |
| Allegheny Research Institute (Melanoma/NSCLC) | Pittsburgh, Pennsylvania, United States | Recruiting |
| M.D. Anderson Cancer Center (Melanoma/NSCLC) | Houston, Texas, United States | Recruiting |
| Melanoma Institute of Australia | Wollstonecraft, New South Wales, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06060613